STOCK TITAN

Innospec REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Nine-month adjusted EBITDA fell to $145.2 million from $147.3 million despite the third-quarter improvement.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Innospec (IOSP) reported third-quarter 2026 revenue of $473.6 million, with all three businesses contributing to sales and operating income growth. Revenue rose 7% year over year. Net income attributable to Innospec increased to $31.8 million, or $1.29 per diluted share, from $12.9 million, or $0.52. Adjusted diluted EPS rose to $1.29 from $1.12, while adjusted EBITDA increased to $51.4 million from $44.2 million.

Performance Chemicals operating income rose 84%, Fuel Specialties increased 1%, and Oilfield Services grew 40%. Operating cash flow fell to $17.4 million from $39.1 million; quarter-end cash was $251.9 million with no debt. The declared $0.94 semi-annual dividend is payable November 25, bringing the annual dividend to $1.86, up 9%. Innospec expects sequential Oilfield Services operating income growth in the fourth quarter after activity delays and elevated raw material costs weighed on third-quarter results.

Loading...
Loading translation...
20 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 12 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter revenue rose 7% to $473.6 million from $441.9 million a year earlier.
  • Moderate pointThird-quarter attributable net income increased to $31.8 million from $12.9 million; diluted EPS reached $1.29 versus $0.52.
  • Moderate pointThird-quarter adjusted diluted EPS increased to $1.29 from $1.12 a year earlier.
  • Moderate pointThird-quarter adjusted EBITDA increased to $51.4 million from $44.2 million a year earlier.
  • Moderate pointThird-quarter GAAP operating income increased to $41.7 million from $5.9 million a year earlier.
  • Moderate pointPerformance Chemicals third-quarter operating income rose 84% to $16.9 million from $9.2 million.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Performance Chemicals expects further growth and margin improvement as new-capacity utilization and new-product progress improve.
  • Moderate pointOilfield Services third-quarter operating income rose 40% to $6.7 million, driven by the recent plant expansion.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Oilfield Services expects sequential fourth-quarter operating income growth as several operating pressures improve.
11 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Annual dividend increased 9% to $1.86; the $0.94 second-half payment is due November 25, 2026.
  • Minor pointQuarter-end liquidity included $251.9 million in cash and cash equivalents and no debt.
  • Minor pointPerformance Chemicals third-quarter revenue rose 6% to $180.5 million, with a positive 12% price and product mix.
  • Minor pointPerformance Chemicals third-quarter gross margin increased 3.7 percentage points to 18.8% year over year.
  • Minor point. Forward-looking: it has not happened yet and may not happen.North Carolina efficiency upgrades are expected to be commissioned by year-end, increasing capacity, productivity and yields.
  • Minor pointFuel Specialties third-quarter revenue rose 5% to $180.7 million; volumes increased 3%, and price and mix increased 2%.
  • Minor pointFuel Specialties third-quarter operating income rose 1% to $35.6 million from $35.3 million.
  • Minor pointOilfield Services third-quarter revenue increased 13% to $112.4 million from $99.1 million.
  • Minor pointNine-month revenue increased to $1,418.2 million from $1,322.4 million a year earlier.
  • Minor pointNine-month attributable net income rose to $93.0 million from $69.2 million; diluted EPS increased to $3.75 from $2.76.
  • Minor pointNine-month GAAP operating income increased to $117.9 million from $82.7 million a year earlier.

Negative

  • Moderate pointThird-quarter operating cash flow declined to $17.4 million from $39.1 million a year earlier.
  • Moderate pointOilfield Services sequential results were lower than expected amid Middle East activity delays and elevated raw material costs.
  • Minor pointCash and cash equivalents declined to $251.9 million from $292.5 million at December 31, 2025.
  • Minor pointNine-month adjusted EBITDA declined to $145.2 million from $147.3 million a year earlier.
  • Minor pointPerformance Chemicals third-quarter volumes fell 5%, with an additional negative currency impact of 1%.
7 minor points
  • Minor pointFuel Specialties third-quarter gross margin fell 0.5 percentage points to 35.1% year over year.
  • Minor pointOilfield Services third-quarter gross margin fell 1.8 percentage points to 28.2% on weaker sales mix.
  • Minor pointThird-quarter corporate costs increased to $18.6 million from $18.2 million a year earlier.
  • Minor pointThird-quarter adjusted effective tax rate increased to 24.7% from 22.7% because of geographical profit mix.
  • Minor pointThird-quarter research and development expense increased to $16.8 million from $13.7 million a year earlier.
  • Minor pointThird-quarter net interest income declined to $0.4 million from $2.2 million a year earlier.
  • Minor pointThird-quarter capital expenditures totaled $15.6 million.
Argus 15 min delay 33 alerts
-16.93% vs previous close $82.43 last price 4.0x rel. volume Open Argus
Details

Market move: IOSP -16.93% vs previous close. 3Q26 earnings report

$81.74 – $99.50 Day Range
$2.03B Mkt Cap at Last Price

On Nov 4, the first trading day after this news, the latest delayed price for IOSP is 16.93% below the previous close. Our momentum scanner has recorded 33 alerts for this stock so far that day. The latest delayed price is $82.43. Relative volume is very high at 4.0x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Revenue: $473.6 million, up 7% from $441.9 million GAAP diluted EPS: $1.29 vs. $0.52 Adjusted non-GAAP EPS: $1.29 vs. $1.12 +5 more
Revenue
$473.6 million, up 7% from $441.9 million
Third quarter 2026 vs. corresponding period in 2025
GAAP diluted EPS
$1.29 vs. $0.52
Third quarter 2026 vs. third quarter 2025
Adjusted non-GAAP EPS
$1.29 vs. $1.12
Third quarter 2026 vs. third quarter 2025
Adjusted EBITDA
$51.4 million vs. $44.2 million
Third quarter 2026 vs. third quarter 2025
Cash from operating activities
$17.4 million vs. $39.1 million
Third quarter 2026 vs. third quarter 2025
Cash and debt
$251.9 million in cash and cash equivalents; no debt
As of September 30, 2026
Annual dividend
$1.86 per share, a 9% increase over 2025
2026 annual dividend
Performance Chemicals operating income
$16.9 million, up 84%
Third quarter 2026 vs. prior-year period

Previous Earnings Reports

2 past events · Latest: Aug 04
Same Type 2 events
  1. Aug 04

    Q2 earnings report

    24h Move
    +6.1%

    Revenue rose 12%, diluted EPS was $1.25, and adjusted EPS was nearly flat.

  2. May 07

    Q1 earnings report

    24h Move
    +5.1%

    Revenue rose 3%, GAAP diluted EPS was $1.22, and adjusted EPS was $1.05.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gaap, non-gaap financial measures, adjusted ebitda, diluted eps, +1 more
5 terms
gaap financial
"GAAP EPS $1.29 and adjusted non-GAAP EPS $1.29"
GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.
View in glossary
non-gaap financial measures financial
"financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
adjusted ebitda financial
"Adjusted EBITDA for the quarter was $51.4 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
diluted eps financial
"Net income attributable to Innospec for the quarter was $31.8 million or $1.29 per diluted share"
Diluted earnings per share (EPS) shows how much profit a company makes for each share of stock, assuming all possible shares from stock options or convertible securities are used. It provides a more conservative estimate than basic EPS, accounting for potential share increases that could dilute ownership. Investors use diluted EPS to get a clearer picture of a company's true profitability on a per-share basis.
contingent consideration financial
"Adjustment to fair value of contingent consideration"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

All businesses contributed to revenue and operating income growth

Continued strength in Fuel Specialties; Double-digit operating income growth in Performance Chemicals and Oilfield Services

Cash flow of $17.4 million generated from operations; Net cash improved to $251.9 million

GAAP EPS $1.29 and adjusted non-GAAP EPS $1.29

Semi-annual dividend of 94 cents; Annual dividend increased by 9 percent

ENGLEWOOD, Colo., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced its financial results for the third quarter ended September 30, 2026 and declared a semi-annual dividend of 94 cents per common share for the second half of 2026, which will be paid on November 25, 2026 to shareholders of record as of November 17, 2026. This brings the annual dividend to $1.86 per share, a 9 percent increase over 2025.

Total revenues for the third quarter were $473.6 million, an increase of 7 percent from $441.9 million in the corresponding period last year. Net income attributable to Innospec for the quarter was $31.8 million or $1.29 per diluted share, compared to $12.9 million or 52 cents per diluted share recorded last year. 

Adjusted EBITDA for the quarter was $51.4 million compared to $44.2 million reported in the same period a year ago. Innospec generated cash from operating activities of $17.4 million, before capital expenditures of $15.6 million in the quarter. The quarter closed with net cash of $251.9 million.

Results for this quarter include some special items, which are summarized in the table below. Excluding these items, adjusted non-GAAP EPS in the third quarter was $1.29 per diluted share, compared to $1.12 per diluted share a year ago.

Adjusted EBITDA and net income attributable to Innospec excluding special items and related per-share amounts together with net cash, are non-GAAP financial measures that are defined and reconciled with GAAP results herein and in the schedules below.

  Quarter ended September 30, 2026
Quarter ended September 30, 2025
             
(in millions, except share and per share data) Net income
attributable
to Innospec
  Diluted
EPS
  Net income
attributable
to Innospec
  Diluted
EPS
 
             
Reported GAAP amounts$31.8 $1.29 $12.9 $0.52 
             
Adjustment to fair value of contingent consideration (1.1) (0.04) (17.7) (0.71)
Amortization of acquired intangible assets 0.8  0.03  1.7  0.07 
Legacy costs of closed operations 0.7  0.03  0.8  0.03 
Foreign currency exchange gains (0.4)  (0.02)  (2.4)  (0.10)
Impairment of property, plant and equipment -  -  18.1  0.73 
Impairment of intangible assets -  -  14.0  0.56 
Restructuring charge -  -  0.6  0.02 
  0.0  0.0  15.1  0.60 
             
Adjusted non-GAAP amounts$31.8 $1.29 $28.0 $1.12 
             

Commenting on the third quarter results, Patrick S. Williams, President and Chief Executive Officer, said,

“This was another good quarter for Innospec with all businesses contributing to solid revenue and strong operating income growth.

Performance Chemicals sales growth and margin improvement drove an 84 percent operating income increase over last year. In North Carolina, we expect to commission our recent plant efficiency upgrades by year-end. These upgrades are expected to increase capacity, productivity and yields on a wide range of personal care and other products. As utilization of this new capacity improves and progress on new products continues, we expect further growth and margin improvement in the coming quarters.

Fuel Specialties had another strong quarter delivering revenue growth and steady operating income with margins that remained within our target range. As expected, the business has continued to deliver consistent results.

Oilfield Services operating income grew 40 percent and operating margins improved, driven by our recent DRA plant expansion. While sequential results were lower than expected on continued activity delays in our legacy Middle East business and elevated raw material costs, we are expecting improvement across several of these areas to drive sequential operating income growth in the fourth quarter.”

Revenues in Performance Chemicals of $180.5 million were up 6 percent from $170.8 million in the third quarter of last year. Volume reductions of 5 percent and a negative currency impact of 1 percent were offset by a positive price and product mix of 12 percent. Gross margins of 18.8 percent increased by 3.7 percentage points from the same quarter last year. Operating income of $16.9 million increased 84 percent from $9.2 million in the prior year period.

Revenues in Fuel Specialties of $180.7 million were up 5 percent from $172.0 million in the third quarter of last year. Volumes were up 3 percent and price and product mix were up 2 percent. Gross margins of 35.1 percent decreased by 0.5 percentage points over last year. Operating income of $35.6 million was up 1 percent from $35.3 million a year ago.

Revenues in Oilfield Services of $112.4 million for the quarter were up 13 percent from $99.1 million in the third quarter of last year. Gross margins of 28.2 percent decreased by 1.8 percentage points from the same quarter last year on a weaker sales mix. Operating income of $6.7 million increased 40 percent from $4.8 million in the prior year period.

Corporate costs for the quarter were $18.6 million, compared with $18.2 million a year ago. The adjusted effective tax rate for the quarter was 24.7 percent compared to 22.7 percent in the same period last year, due to the geographical mix of taxable profits.

For the quarter, cash provided by operating activities was $17.4 million compared to $39.1 million a year ago. As of September 30, 2026, Innospec had $251.9 million in cash and cash equivalents and no debt. 

Mr. Williams concluded,

“Again this quarter Innospec delivered solid sales and strong operating income growth with higher margins. We remain focused on significant opportunities for continued growth and margin improvement across all our businesses and in particular Performance Chemicals and Oilfield Services.

Operating cash generation was positive in the quarter, and our net cash position remained at over $250 million. We continue to focus on driving increased operating cash flow in the coming quarters with better working capital efficiency. We have significant balance sheet flexibility for organic investment, M&A, dividend growth, and buybacks. This quarter our Board approved a further increase in our semi-annual dividend to 94 cents per share resulting in an annual dividend increase of 9 percent.”

Use of Non-GAAP Financial Measures

The information presented in this press release includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise adjusted EBITDA, net income attributable to Innospec excluding special items and related per share amounts together with net cash. Adjusted EBITDA is net income attributable to Innospec per our consolidated financial statements adjusted for the exclusion of interest income, net, income taxes, depreciation and amortization, foreign currency exchange (gains)/losses, legacy costs of closed operations, adjustment to fair value of contingent consideration, restructuring charge, impairment of property, plant and equipment and impairment of intangible assets. Net income attributable to Innospec and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of adjustment to fair value of contingent consideration, amortization of acquired intangible assets, legacy costs of closed operations, foreign currency exchange gains, impairment of property, plant and equipment, impairment of intangible assets and restructuring charge. Net cash is cash and cash equivalents less total debt. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the schedules below. 

The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company’s underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company’s performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company’s performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and net income attributable to Innospec excluding special items and adjusted EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income attributable to Innospec) to allocate resources and evaluate the performance of the Company’s operations and has provided a reconciliation of adjusted EBITDA and net income attributable to Innospec excluding special items, and related per share amounts, to GAAP net income attributable to Innospec herein and in the schedules below.

About Innospec Inc.

Innospec Inc. is an international specialty chemicals company with approximately 2,450 employees in 22 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care, Home Care, Agrochemical, Mining and Industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil and gas exploration and production industry.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plans,” “intends,” “outlook” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2025, Innospec’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Corbin Barnes
Innospec Inc.
+44-151-355-3611
corbin.barnes@innospecinc.com

 
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Schedule 1
 
(in millions, except share and per share data) Three Months Ended
September 30
  Nine Months Ended
September 30

 
2026   2025  2026   2025 
             
Net sales$473.6 $441.9 $1,418.2 $1,322.4 
Cost of goods sold (344.5) (325.2) (1,027.3) (957.4)
Gross profit 129.1  116.7  390.9  365.0 
             
Operating expenses:            
Selling, general and administrative (71.7)  (71.9)  (234.5)  (215.8)
Research and development (16.8)  (13.7)  (44.2)  (40.0)
Adjustment to fair value of contingent consideration 1.1  17.7  5.7  16.2 
Restructuring charge -  (0.9)  -  (0.9)
Impairment of property, plant and equipment -  (22.9)  -  (22.9)
Impairment of intangible assets -  (19.1)  -  (19.1)
Profit on disposal of property, plant and equipment -  -  -  0.2 
Total operating expenses (87.4)  (110.8)  (273.0)  (282.3)
Operating income 41.7  5.9  117.9  82.7 
Other income/(expense), net 0.5  3.2  4.2  (1.2)
Interest income, net 0.4  2.2  2.0  7.3 
Income before income taxes 42.6  11.3  124.1  88.8 
Income taxes (11.0)  1.4  (30.5)  (18.6)
Net income 31.6  12.7  93.6  70.2 
Net loss/(income) attributable to non-controlling interests 0.2  0.2  (0.6)  (1.0)
Net income attributable to Innospec$31.8 $12.9 $93.0 $69.2 
             
Earnings per share:            
Basic$1.29 $0.52 $3.77 $2.78 
Diluted$1.29 $0.52 $3.75 $2.76 
             
Weighted average shares outstanding (in thousands):            
Basic 24,631  24,834  24,684  24,914 
Diluted 24,743  24,909  24,802  25,045 
             


 
INNOSPEC INC. AND SUBSIDIARIES
Schedule 2A
 
SEGMENTAL ANALYSIS OF RESULTS Three Months Ended
September 30

  Nine Months Ended
September 30

 
(in millions) 2026  2025  2026  2025 
             
Net sales:            
Performance Chemicals$180.5 $170.8 $540.2 $513.0 
Fuel Specialties 180.7  172.0  548.0  507.4 
Oilfield Services 112.4  99.1  330.0  302.0 
  473.6  441.9  1,418.2  1,322.4 
             
Gross profit:            
Performance Chemicals 34.0  25.8  95.4  91.6 
Fuel Specialties 63.4  61.2  195.7  184.9 
Oilfield Services 31.7  29.7  99.8  88.5 
  129.1  116.7  390.9  365.0 
             
Operating income:            
Performance Chemicals 16.9  9.2  44.0  43.3 
Fuel Specialties 35.6  35.3  109.7  107.6 
Oilfield Services 6.7  4.8  21.0  15.1 
Corporate costs (18.6) (18.2) (62.5) (56.8)
  40.6  31.1  112.2  109.2 
Adjustment to fair value of contingent consideration 1.1  17.7  5.7  16.2 
Restructuring charge -  (0.9) -  (0.9)
Impairment of property, plant and equipment -  (22.9) -  (22.9)
Impairment of intangible assets -  (19.1) -  (19.1)
Profit on disposal of property, plant and equipment -  -  -  0.2 
Total operating income$41.7 $5.9 $117.9 $82.7 
             


 Schedule 2B
 
NON-GAAP MEASURES Three Months Ended
September 30

  Nine Months Ended
September 30

(in millions) 2026  2025  2026  2025 
             
Net income attributable to Innospec$31.8 $12.9 $93.0 $69.2 
Interest income, net (0.4) (2.2) (2.0) (7.3)
Income taxes 11.0  (1.4) 30.5  18.6 
Depreciation and amortization 9.7  11.9  29.5  34.2 
Foreign currency exchange (gains)/losses (0.5) (3.2) (4.2) 1.1 
Legacy costs of closed operations 0.9  1.0  4.1  4.8 
Adjustment to fair value of contingent consideration (1.1) (17.7) (5.7) (16.2)
Restructuring charge -  0.9  -  0.9 
Impairment of property, plant and equipment -  22.9  -  22.9 
Impairment of intangible assets -  19.1  -  19.1 
Adjusted EBITDA 51.4  44.2  145.2  147.3 
             


Schedule 3
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
 

(in millions)
 September 30,
2026
 December 31,
2025
Assets  
     
Current assets:    
Cash and cash equivalents$251.9$292.5
Trade and other accounts receivable 395.6 342.3
Inventories 361.8 329.3
Prepaid expenses 10.0 20.1
Prepaid income taxes 2.7 13.1
Other current assets 12.4 7.3
Total current assets 1,034.4 1,004.6
     
Net property, plant and equipment 300.2 286.1
Operating lease right-of-use assets 47.3 52.7
Goodwill 397.4 399.0
Other intangible assets 62.5 67.7
Deferred tax assets 13.5 13.6
Other non-current assets 1.3 8.7
Total assets$1,856.6$1,832.4
     
Liabilities and Stockholders’ Equity    
     
Current liabilities:    
Accounts payable$164.4$174.7
Accrued liabilities 157.5 152.3
Current portion of operating lease liabilities 13.5 15.9
Current portion of plant closure provisions 4.9 4.9
Current portion of acquisition-related contingent consideration 2.5 7.0
Accrued income taxes 8.4 5.3
Total current liabilities 351.2 360.1
     
Operating lease liabilities, net of current portion 33.8 36.8
Plant closure provisions, net of current portion 58.8 60.2
Deferred tax liabilities 15.8 19.1
Pension liabilities and post-employment benefits 12.5 13.2
Acquisition-related contingent consideration, net of current portion 0.5 1.3
Other non-current liabilities 3.7 8.8
Equity 1,380.3 1,332.9
Total liabilities and equity$1,856.6$1,832.4
     


Schedule 4
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 
  Nine Months Ended
September 30
 
(in millions) 2026  2025 
       
Cash Flows from Operating Activities      
       
Net income$93.6 $70.2 
Adjustments to reconcile net income to cash provided by operating activities:      
Depreciation and amortization 29.5  34.2 
Adjustment to fair value of contingent consideration (5.7) (14.9)
Impairment of property, plant and equipment -  22.9 
Impairment of intangible assets -  19.1 
Deferred taxes (3.0) (10.6)
Profit on disposal of property, plant and equipment -  (0.2)
Movements on defined benefit pension plans (0.2) 2.6 
Stock option compensation 5.2  5.0 
Changes in working capital (87.4) (24.4)
Movements in plant closure provisions 0.5  1.1 
Movements in income taxes 11.8  (19.9)
Movements in other assets and liabilities (2.1) (7.2)
Net cash provided by operating activities 42.2  77.9 
       
Cash Flows from Investing Activities      
       
Capital expenditures (42.4) (35.7)
Proceeds on disposal of property, plant and equipment 1.7  0.4 
Business combinations, net of cash acquired -  (2.0)
Internally developed software (5.1) (18.6)
Net cash used in investing activities (45.8) (55.9)
       
Cash Flows from Financing Activities      
       
Dividend paid (22.7) (20.8)
Issue of treasury stock 0.2  0.4 
Repurchase of common stock (13.5) (23.9)
Net cash used in financing activities (36.0) (44.3)
       
Effect of foreign currency exchange rate changes on cash (1.0) 3.9 
Net change in cash and cash equivalents (40.6) (18.4)
Cash and cash equivalents at beginning of period 292.5  289.2 
Cash and cash equivalents at end of period$251.9 $270.8 



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Innospec's third-quarter 2026 earnings and revenue?

Innospec reported revenue of $473.6 million and attributable net income of $31.8 million, or $1.29 per diluted share. A year earlier, revenue was $441.9 million and attributable net income was $12.9 million, or $0.52 per diluted share. Adjusted diluted EPS increased to $1.29 from $1.12.

When does Innospec expect its North Carolina plant upgrades to be commissioned?

Innospec expects to commission its North Carolina plant efficiency upgrades by year-end. The company expects the upgrades to increase capacity, productivity and yields across a range of personal care and other products.

Keep reading